Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THP
Marcin Kubeczko(The Maria Sklodowska-Curie National Research Institute of Oncology), F. Braso-Maritany(Breast Cancer Research Foundation), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Jesús Soberino(Hospital Quirónsalud Barcelona), Bartłomiej Pyciński(Silesian Center for Heart Disease), M. Rey(Breast Cancer Research Foundation), María José Senent Vidal(Breast Cancer Research Foundation), B. Adamo(Hospital Clínic de Barcelona), Esther Sanfeliu(Breast Cancer Research Foundation), Ewa Chmielik(National Institute of Oncology), Malgorzata Oczko-Wojciechowska(National Institute of Oncology), L. Pare(Oryzon Genomics (Spain)), E. Ciruelos(Breast Cancer Research Foundation), F. Pardo(Oryzon Genomics (Spain)), A. Aguirre(Breast Cancer Research Foundation), J. Maues(Roland Park Country School), A. Prat(Breast Cancer Research Foundation), A. Lesniak(The Maria Sklodowska-Curie National Research Institute of Oncology), M. Bergamino(Hospital Clínic de Barcelona), Esther Carcelero(Hospital Clínic de Barcelona), M. Jarzab(The Maria Sklodowska-Curie National Research Institute of Oncology), Sandra Cobo(Breast Cancer Research Foundation)
Cited by 0
Related Papers
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
|Cancer Medicine|2021|134